Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kezar Life Sciences (KZR)
:KZR
Holding KZR?
Track your performance easily
KZR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.20 - $11.35
Previous CloseN/A
Volume19.48K
Average Volume (3M)53.37K
Market Cap
$47.50M
Enterprise Value-$75.06M
Total Cash (Recent Filing)$9.75M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Mar 13, 2025EPS Estimate
-2.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.15
Shares Outstanding7,296,222
10 Day Avg. Volume38,008
30 Day Avg. Volume53,367
Standard Deviation0.23
R-Squared0.00218
Alpha-0.00448
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.79
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.72
Enterprise Value/Ebitda0.82
Forecast
1Y Price Target
$9.00Price Target Upside42.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Kezar Life Sciences News
Bulls Say, Bears Say
Bulls Say
Business DevelopmentPotential exists for favorable monetization of zetomipzomib through business development opportunities.
Clinical TrialsNo Grade 4 or Grade 5 severe adverse events have been observed in the PORTOLA trial.
Financial PerformanceKezar ended 3Q24 with approximately $148 million in cash, cash equivalents, and marketable securities, which is expected to last well into 2025.
Bears Say
Financial PerformanceKezar Life Sciences reported a net loss of $2.78 per share in 3Q24, which is wider than the forecasted net loss of $0.23 per share.
Program Safety ConcernsIn October Kezar discontinued the PALIZADE Ph 2b trial of zetomipzomib in lupus nephritis following the report of n=4 fatal adverse events.
Regulatory ChallengesA partial clinical hold has been placed on Phase 2a of zetomipzomib in autoimmune hepatitis by the FDA, adding uncertainty to the program.
---
Ownership Overview
13.53% Insiders
12.95% Mutual Funds
18.59% Other Institutional Investors
51.08% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KZR FAQ
What was Kezar Life Sciences’s price range in the past 12 months?
Kezar Life Sciences lowest stock price was $5.20 and its highest was $11.35 in the past 12 months.
What is Kezar Life Sciences’s market cap?
Kezar Life Sciences’s market cap is $47.50M.
When is Kezar Life Sciences’s upcoming earnings report date?
Kezar Life Sciences’s upcoming earnings report date is Mar 13, 2025 which is in 57 days.
How were Kezar Life Sciences’s earnings last quarter?
Kezar Life Sciences released its earnings results on Nov 12, 2024. The company reported -$2.78 earnings per share for the quarter, beating the consensus estimate of -$3.148 by $0.368.
Is Kezar Life Sciences overvalued?
According to Wall Street analysts Kezar Life Sciences’s price is currently Undervalued.
Does Kezar Life Sciences pay dividends?
Kezar Life Sciences does not currently pay dividends.
What is Kezar Life Sciences’s EPS estimate?
Kezar Life Sciences’s EPS estimate is -2.72.
How many shares outstanding does Kezar Life Sciences have?
Kezar Life Sciences has 7,296,222 shares outstanding.
What happened to Kezar Life Sciences’s price movement after its last earnings report?
Kezar Life Sciences reported an EPS of -$2.78 in its last earnings report, beating expectations of -$3.148. Following the earnings report the stock price went up 0.668%.
Which hedge fund is a major shareholder of Kezar Life Sciences?
Among the largest hedge funds holding Kezar Life Sciences’s share is Wexford Capital LP. It holds Kezar Life Sciences’s shares valued at 0.
---
Kezar Life Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (42.86% Upside)
$9.00 (42.86% Upside)
Blogger Sentiment
Bullish
KZR Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.11%
12-Months-Change
Fundamentals
Return on Equity
-71.45%
Trailing 12-Months
Asset Growth
-34.19%
Trailing 12-Months
Company Description
Kezar Life Sciences
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which discovers and develops novel small molecule therapeutics to treat autoimmunity and cancer. The firm specializes in the areas of protein degradation and protein secretion to discover & develop novel therapies for the treatment of serious and unmet medical needs. Its product include KZR-616, an immunoproteasome inhibitor, has completed testing in healthy volunteers. The company was founded by John Fowler, Christopher J. Kirk and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
---
KZR Stock 12 Month Forecast
Average Price Target
$9.00
▲(42.86% Upside)
Technical Analysis
Cue Biopharma
―
Corbus Pharmaceuticals
―
Immuneering
―
Karyopharm Therapeutics
―
Rigel
―
Solid Biosciences
―
Best Analysts Covering KZR
1 Year
1 Year Success Rate
6/17 ratings generated profit
1 Year Average Return
-18.22%
reiterated a buy rating 2 months ago
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 35.29% of your transactions generating a profit, with an average return of -18.22% per trade.
---